6/28/23, 1:17 AM DIVA Pathway Feedback Search Clinical Topics Home Studies DIVA DIVA Disease Coronary artery disease Trial question What is the role of drug-eluting stents in patients undergoing stenting of de-novo saphenous vein bypass graft lesions? Study design Multi-center Double blinded RCT Population 599 patients (2 female, 595 male) Inclusion criteria: patients who had at least one significant de-novo SVG lesion requiring PCI with intent to use embolic protection devices Key exclusion criteria: planned noncardiac surgery within 12 months of screening, ST-segment elevation acute myocardial infarction, target SVG that was the last remaining vessel or was a left main equivalent, previous percutaneous treatment of the target vessel within the previous 12 months, or hemorrhagic diatheses Interventions N=292 drug-eluting stents (coronary revascularization with drug-eluting stents) N=305 bare metal stents (coronary revascularization with bare metal stents) Primary outcome Myocardial infarction during follow-up 10.0 % 10 10 7.5 % 5.0 % 2 5 % https://web.pathway.md/studies/recjr2NZ687dsk2zu 1/2 6/28/23, 1:17 AM 2.5 % DIVA Pathway No significant difference 0.0 % Drug-eluting stents Bare metal stents No significant difference in myocardial infarction during follow-up (10% vs. 10%; HR 0.94, 95% CI 0.56 to 1.57) Secondary outcomes No significant difference in revascularization (19% vs. 17%; HR 1.11, 95% CI 0.76 to 1.61) Safety outcomes No significant difference in serious adverse events. Conclusion In patients who had at least one significant de-novo SVG lesion requiring PCI with intent to use embolic protection devices, drug-eluting stents were not superior to bare metal stents with respect to myocardial infarction during follow-up. Reference Brilakis ES, Edson R, Bhatt DL et al. Drug-eluting stents versus bare-metal stents in saphenous vein grafts: a double-blind, randomised trial. Lancet. 2018 May 19;391(10134):1997-2007. Open reference URL https://web.pathway.md/studies/recjr2NZ687dsk2zu 2/2